WO2019020807A1 - Cd9p-1-targeting antibody and uses thereof - Google Patents

Cd9p-1-targeting antibody and uses thereof Download PDF

Info

Publication number
WO2019020807A1
WO2019020807A1 PCT/EP2018/070469 EP2018070469W WO2019020807A1 WO 2019020807 A1 WO2019020807 A1 WO 2019020807A1 EP 2018070469 W EP2018070469 W EP 2018070469W WO 2019020807 A1 WO2019020807 A1 WO 2019020807A1
Authority
WO
WIPO (PCT)
Prior art keywords
cd9p
pathway
targeting antibody
inhibits
stabilin
Prior art date
Application number
PCT/EP2018/070469
Other languages
French (fr)
Inventor
Sylvie Colin
Original Assignee
Gene Signal International Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Signal International Sa filed Critical Gene Signal International Sa
Priority to JP2020526686A priority Critical patent/JP2020528932A/en
Priority to US16/634,407 priority patent/US20200172618A1/en
Priority to CN201880062968.3A priority patent/CN111542538A/en
Priority to EP18745623.1A priority patent/EP3676291A1/en
Publication of WO2019020807A1 publication Critical patent/WO2019020807A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present disclosure relates to an isolated protein that inhibits the CD9P-1 pathway, preferably that inhibits the CD9P-1 / stabilin-1 pathway and/or the CD9P-1 / TRAF-2 pathway, in particular to an isolated antibody against human CD9P-1, and to the use thereof in therapeutic or diagnostic methods.
PCT/EP2018/070469 2017-07-28 2018-07-27 Cd9p-1-targeting antibody and uses thereof WO2019020807A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020526686A JP2020528932A (en) 2017-07-28 2018-07-27 CD9P-1 Targeted Antibody and Its Use
US16/634,407 US20200172618A1 (en) 2017-07-28 2018-07-27 Cd9p-1-targeting antibody and uses thereof
CN201880062968.3A CN111542538A (en) 2017-07-28 2018-07-27 CD 9P-1-targeting antibodies and uses thereof
EP18745623.1A EP3676291A1 (en) 2017-07-28 2018-07-27 Cd9p-1-targeting antibody and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762538106P 2017-07-28 2017-07-28
EP17306017.9 2017-07-28
US62/538,106 2017-07-28
EP17306017 2017-07-28

Publications (1)

Publication Number Publication Date
WO2019020807A1 true WO2019020807A1 (en) 2019-01-31

Family

ID=59761882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/070469 WO2019020807A1 (en) 2017-07-28 2018-07-27 Cd9p-1-targeting antibody and uses thereof

Country Status (1)

Country Link
WO (1) WO2019020807A1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0404097A2 (en) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6162963A (en) 1990-01-12 2000-12-19 Abgenix, Inc. Generation of Xenogenetic antibodies
WO2012120125A1 (en) * 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
WO2015121428A1 (en) 2014-02-14 2015-08-20 Gene Signal International Sa Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
WO2017121771A1 (en) 2016-01-11 2017-07-20 Blink Biomedical Sas Humanized, mouse or chimeric anti-cd47 monoclonal antibodies

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0404097A2 (en) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
US6162963A (en) 1990-01-12 2000-12-19 Abgenix, Inc. Generation of Xenogenetic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO2012120125A1 (en) * 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
WO2015121428A1 (en) 2014-02-14 2015-08-20 Gene Signal International Sa Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
WO2017121771A1 (en) 2016-01-11 2017-07-20 Blink Biomedical Sas Humanized, mouse or chimeric anti-cd47 monoclonal antibodies

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
"Basic and Clinical Immunology", 1994, APPLETON & LANGE
"Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS
"Computational Molecular Biology", 1988, OXFORD UNIVERSITY PRESS
"Computer Analysis of Sequence Data", 1994, HUMANA PRESS
"Genetics Computer Group", UNIVERSITY OF WISCONSIN
"Sequence Analysis Primer", 1991, M. STOCKTON PRESS
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL.: "BLAST Manual", NCB/NLM/NIH BETHESDA
CARILLO ET AL., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073
CARTER ET AL., PNAS, vol. 89, 1992, pages 4285
CHARRIN S ET AL: "The major CD9 and CD81 molecular partner: Identification and characterization of the complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 276, no. 17, 27 April 2001 (2001-04-27), pages 14329 - 14337, XP002219161, ISSN: 0021-9258 *
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, pages 901
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DELGADO ET AL., BR. J. CANCER, vol. 73, no. 2, 1996, pages 175 - 182
DEVEREUX ET AL., NUCL. ACID. RES., vol. 2, 1984, pages 387
GOENAGA A L ET AL: "Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 15, 1 July 2007 (2007-07-01), pages 3777 - 3788, XP025320896, ISSN: 0161-5890, [retrieved on 20070530], DOI: 10.1016/J.MOLIMM.2007.03.023 *
GREEN ET AL., NATURE GENET, vol. 7, 1994, pages 13
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HONNEGER, A.; PLUNKTHUN, A., J. MOL. BIOL., vol. 309, 2001, pages 657 - 670
JAKOBOVITZ ET AL., NATURE, vol. 362, 1993, pages 255
JONES ET AL., NATURE, vol. 321, 1986, pages 522
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
LEFRANC, M. P. ET AL., NUCL. ACIDS RES., vol. 27, 1999, pages 209 - 212
LEONG ET AL., CYTOKINES, vol. 16, no. 3, 2001, pages 106 - 119
LIN WENG ET AL: "The Monoclonal Antibodies 18d7/91f2 Recognize a Receptor Regulatory Protein on Mouse Bone Marrow Stromal Cells", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 15, no. 7, 1 July 2000 (2000-07-01), US, pages 1286 - 1300, XP055433095, ISSN: 0884-0431, DOI: 10.1359/jbmr.2000.15.7.1286 *
LONBERG, NATURE, vol. 368, 1994, pages 856
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 553
MORRISON ET AL., PNAS, vol. 6851, 1984
MORRISON ET AL., PROC. NATL. ACAD. SCI. U. S. A., 1984, pages 6851
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
PRESTA ET AL., CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
PRESTA, J. IMMUNOL., vol. 51, 1993
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
RUIZ, M. ET AL., NUCL. ACIDS RES., vol. 28, 2000, pages 219 - 221
S COLIN ET AL: "A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth", BRITISH JOURNAL OF CANCER, vol. 105, no. 7, 23 August 2011 (2011-08-23), GB, pages 1002 - 1011, XP055433172, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.303 *
SCATCHARD ET AL., ANN. N.Y. ACAD. SCI. USA, vol. 51, 1949, pages 660
SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
TAYLOR ET AL., INT IMMUN, vol. 6, 1994, pages 579
VERHOEYEN ET AL., SCIENCE, vol. 239, pages 1534
VON HEINJE, G.: "Sequence Analysis in Molecular Biology", 1987, ACADEMIC PRESS
W GUILMAIN ET AL: "CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth", BRITISH JOURNAL OF CANCER, vol. 104, no. 3, 4 January 2011 (2011-01-04), GB, pages 496 - 504, XP055433165, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6606033 *
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062

Similar Documents

Publication Publication Date Title
GEP20237528B (en) Antibodies against signal-regulatory protein alpha and methods of use
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
AU2018278327A1 (en) Activatable anti-pdl1 antibodies and methods of use thereof
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2021006786A (en) Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof.
PH12018501882A1 (en) Binding proteins and methods of use thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MX2018014175A (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE.
WO2018081648A8 (en) Anti-mic antibodies and methods of use
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
MX2019011624A (en) Methods and compositions for reduction of immunogenicity.
EP3680331A4 (en) Modified cas9 protein, and use thereof
PH12020551716A1 (en) Anti-ror antibody constructs
EP3683236A4 (en) Antibody against human dlk1 and use thereof
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
MX2020006372A (en) HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION.
MX2018002546A (en) Compositions comprising an urolithin compound.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2018009499A (en) Egfl6 specific monoclonal antibodies and methods of their use.
WO2015153997A3 (en) Notch3 antibodies and uses thereof
WO2017019957A3 (en) Binding proteins and methods of use thereof
EP3630124A4 (en) Synthetic composition comprising oligosaccharides and its use in medical treatment.
EP4011919A3 (en) Relaxin immunoglobulin fusion proteins and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18745623

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020526686

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018745623

Country of ref document: EP

Effective date: 20200228